New drug cocktail aims to tame myeloma in seniors
NCT ID NCT05572229
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This study is testing a new drug called teclistamab, given as a shot, together with either daratumumab (another shot) or lenalidomide (a pill) in people aged 65 and older who have just been diagnosed with multiple myeloma and cannot have a stem cell transplant. The goal is to see if these combinations are safe and can shrink the cancer significantly after four cycles of treatment. About 74 participants will be enrolled across multiple centers.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Teclistamab (a drug given as a shot under the skin) combined with either daratumumab (shot) or lenalidomide (pill)
- What this could lead to
- If successful, this could offer a new, effective treatment option for elderly patients with newly diagnosed multiple myeloma who cannot undergo a stem cell transplant.
- What could go wrong
- This is a Phase 2 trial with only 74 participants, so results are preliminary. The combination may cause side effects or not work as well as hoped.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Aphp - Chu Henri Mondor
ACTIVE_NOT_RECRUITINGParis, France
-
Aphp - Hopital Saint Antoine
NOT_YET_RECRUITINGParis, France
-
Aphp - Hopital Saint Louis
NOT_YET_RECRUITINGParis, France
-
Aphp Hopital Avicenne
NOT_YET_RECRUITINGBobigny, France
-
Centre Hospitalier de La Cote Basque
RECRUITINGBayonne, France
-
Centre Hospitalier de Versailles
RECRUITINGLe Chesnay, France
-
Centre Leon Berard
NOT_YET_RECRUITINGLyon, France
-
Ch D'Avignon
ACTIVE_NOT_RECRUITINGAvignon, France
-
Ch de Dunkerque
ACTIVE_NOT_RECRUITINGDunkirk, France
-
Chr Metz-Thionville
RECRUITINGMetz, France
-
Chru Angers
RECRUITINGAngers, France
-
Chru Bretonneau
RECRUITINGTours, France
-
Chru de Nancy, Hopitaux de Brabois
RECRUITINGNancy, France
-
Chu Amiens - Hopital Sud
RECRUITINGAmiens, France
-
Chu Bordeaux
RECRUITINGPessac, France
-
Chu Dijon Bourgogne
RECRUITINGDijon, France
-
Chu Limoges
ACTIVE_NOT_RECRUITINGLimoges, France
-
Chu Montpellier
RECRUITINGMontpellier, France
-
Chu Pontchaillou
ACTIVE_NOT_RECRUITINGRennes, France
-
Chu de Besancon
RECRUITINGBesançon, France
-
Chu de Caen
RECRUITINGCaen, France
-
Chu de Grenoble
RECRUITINGLa Tronche, France
-
Chu de Lille, Hopital Claude Huriez
RECRUITINGLille, France
-
Chu de Nantes Site Hotel Dieu
ACTIVE_NOT_RECRUITINGNantes, France
-
Chu de Poitiers
RECRUITINGPoitiers, France
-
Chu de Reims
NOT_YET_RECRUITINGReims, France
-
Hopital E. Muller- Ghrmsa
NOT_YET_RECRUITINGMulhouse, France
-
Hopitaux Universitaire de Strasbourg - Hopital Hautepierre
RECRUITINGStrasbourg, France
-
Oncopole Chu Toulouse
RECRUITINGToulouse, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could muscle loss predict blood cancer outcomes?
- Can a Triple-Action antibody deepen remissions in myeloma?
- Can a Low-Dose antifungal shield vulnerable patients from deadly fungal infections?
- Can a gentler chemo prep make stem cell transplants safer for blood cancer patients?
- Talking about the end: could guided conversations reduce futile cancer treatments?
- A guided path back to work after blood cancer: a trial tests the impact